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WILLINGNESS TO PAY PER QUALITY ADJUSTED LIFE-YEAR: IS ONE 
THRESHOLD APPLICABLE FOR ALL DECISION-MAKING?
Zhao FL1, Yue M2, Yang H3, Wang T3, Wu JH2, Li SC1
1University of Newcastle, Callaghan, NSW, Australia; 2306 Hospital of PLA, Beijing, China; 
3The First People’s Hospital of Yunnan Province, Kunming, Yunnan, China
OBJECTIVES: To estimate the Willingness to pay (WTP) per quality-adjusted life-year 
(QALY) ratio with the stated preference data and compare the results obtained 
between chronic prostatits (CP) patients and general population. METHODS: CP 
patients were recruited from two tertiary referral hospitals and the general populations 
were randomly approached in China at the beginning of 2009. WTP per QALY was 
calculated with a formula combining the subjects’ own health-related utility and the 
WTP value. Two widely used preference-based health-related quality of life instru-
ments, EQ-5D and SF-6D, were used to elicit utility for participants’ own health. The 
monthly WTP values for moving from participants’ current health to a perfect health 
described by “11111” status of EQ-5D were elicited using closed-ended iterative 
bidding contingent valuation method. RESULTS: A total of 268 CP patients and 364 
participants from general population completed the questionnaire. We obtained four 
WTP/QALY ratios ranging from $4700 to $7400, which were lower than the pro-
posed thresholds and published researches eliciting the preference for avoiding the risk 
of death. In addition, the WTP/QALY ratios from the general population were signiﬁ -
cantly lower than those from the CP patients and different determinants were associ-
ated with the within group variation identiﬁ ed by multiple linear regression. 
CONCLUSIONS: Preference elicitation methods are acceptable and feasible in the 
socio-cultural context of an Asian environment and the calculation of WTP/QALY 
produced meaningful answers. The lower WTP/QALY elicited than published values 
and higher value from CP patients compared with the general population highlight 
the necessity of considering disease speciﬁ c QALY in estimating WTP/QALY. Our 
results inferred that one threshold might not be enough to serve all decision-making 
under different situations. Further studies using the same methods to conﬁ rm whether 
the WTP/QALY value would be dissimilar among diseases with different impact on 
QoL would be needed. 
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OBJECTIVES: Probabilistic sensitivity analysis (PSA) is a useful tool to assess param-
eter uncertainty, but being among the more technically advanced methods in cost 
effectiveness modeling, it is sometimes underutilized. However, following the incor-
poration of PSA by NICE, the English HTA agency, into their guidelines in 2005, 
there was a call for the routine use of PSA in economic modeling. This study investi-
gates whether these two developments have had an effect on cost-effectiveness model-
ing practice, and also reviews current requirements for PSA in reimbursement 
guidelines globally. METHODS: The following three journals in which cost effective-
ness analyses are most often published were included in the study: Medical Decision 
Making, Pharmacoeconomics and Value in Health. All papers published in these three 
journals in 2004 and 2009 respectively were assessed. In addition, pharmacoeconomic 
guidelines from 31 countries were compared for the requirement of PSA in reimburse-
ment submissions. RESULTS: In the three journals from 2004 to 2009, the overall 
number of articles presenting cost-effectiveness modeling increased from 41 (2004) to 
55 (2009). In 2009, 69% of these articles presented PSA, compared to only 32% in 
2004. Of a total of 31 national pharmacoeconomic guidelines, 12 mention PSA. 
However, only six of these require this form of analysis to be included in reimburse-
ment submissions. Many countries with well established requirements for economic 
analysis in reimbursement submissions, such as Australia, do not require PSA. CON-
CLUSIONS: The usage of PSA to investigating parameter uncertainty is now common 
and increasing. The trend is also starting to show in the reimbursement agencies’ 
guidelines. 
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OBJECTIVES: The evidence needs of payers in mainland China at the national, 
regional and local hospital level are poorly understood. As such, analysis is required 
to capture payer preferences regarding evidence submissions from pharmaceutical 
companies and identify emerging trends in value evidence needs. METHODS: A 
qualitative telephone survey of 30 key payers in Tier 3A hospitals, provincial funding 
bodies and national decision-making groups was conducted. Respondents were asked 
to score the impact of the following value attributes in their routine assessment of 
health-care products for formulary listing and/or reimbursement: 1) Innovation; 2) 
Health-related quality of life; 3) Unmet need; 4) Cost effectiveness; 5) Price; 6) Budget 
impact; 7) Safety; 8) Efﬁ cacy in head-to-head trials; and 9) Efﬁ cacy in selected popula-
tions. Scores derived were weighted according to a market impact assessment in order 
to derive maximal scores for each evidence type. RESULTS: Hospital payers reported 
that budget impact was the least signiﬁ cant evidence type (Score 5.6), due to the “self-
pay” model of patient access in China. Among hospital and provincial payers, price 
was the second least signiﬁ cant attribute (Score 6.3), due to the separation of pricing 
functions and assessment of clinical evidence in China. However, efﬁ cacy in head-to-
head studies (Score 7.5) and safety (Score 8.3) were the most desired attributes. 
CONCLUSIONS: Awareness of cost-effectiveness is at an early stage in major hospi-
tals in China; the key attributes continue to be safety and efﬁ cacy. However, there is 
a trend toward requirement of health-related quality of life data at the national payer 
level, particularly regarding oncology medicines. Further research is needed in this 
area, in order to gain a more detailed understanding from the pharmaceutical company 
perspective. 
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Chan HYH, Steadman KJ, Hollingworth S, Nissen LM
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OBJECTIVES: To examine the health-care systems of China, Hong Kong, Vietnam, 
Thailand, Malaysia, Singapore and Australia using a pre-determined set of indicators. 
These were used to assess each system in terms of accessibility, effectiveness, efﬁ ciency, 
quality and responsiveness. METHODS: This study was a qualitative study. A set of 
indicators and sub-indicators was developed based on indicators used by the World 
Health Organisation, United Nations, the Organisation for Economic Co-operation 
Development (Health Care Quality Indicator Project), and from health frameworks 
of Australia, New Zealand, Canada, USA and UK. The indicators were used to assess 
health-care systems from an operational perspective. A literature search and interviews 
with relevant academics and government ofﬁ cials were conducted to address each 
indicator. This provided a more comprehensive view of the functioning of each health-
care system and how the system itself is regulated and provides health-care services 
to its people. RESULTS: Each of the surveyed countries have certain measures or 
programs in place to address health-care accessibility. The majority of the countries 
have clear guidelines to improve effectiveness and efﬁ ciency. However, most develop-
ing Asian countries lack clear programs to assess the quality and responsiveness of 
their health-care systems. CONCLUSIONS: Different countries have different health 
considerations and priorities in terms of politics, ﬁ nance and resources where health-
care systems are concerned. Each has its respective strengths and weaknesses. What 
is appropriate for one country may not be suitable for another. This evaluation pro-
vided clarity and insight into the operation of each system and highlighted areas that 
require further attention. Interviews with local academics, government ofﬁ cials and 
other health-care stakeholders in each country yielded a more comprehensive and 
in-depth understanding on the functioning of each health-care system. 
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OBJECTIVES: To understand the historical climate through which ten Asian markets 
arrived at the establishment of an HTA authoritative body, and the extent to which 
pharmacoeconomic evaluations have evolved in each of these markets. METHODS: 
Secondary and primary research was conducted in South Korea, Thailand, Philippines, 
Taiwan, Singapore, Malaysia, Indonesia, India, China and Japan to examine political 
and economic changes over the last 30 years. The results were compiled and analyzed 
along with other metrics, such as pricing legislation, health-care coverage, and HTA 
development to determine a correlative pattern for Asian pharmacoeconomic develop-
ment. RESULTS: While three of the studied markets are exceptions to the trend, we 
believe the other seven will follow the a discernible course of events. A change in 
political climate, desire for universal health care, ﬁ nancial crisis and strong develop-
ment of a national formulary are all policy objectives and events along the path toward 
HTA development. HTA establishment in those seven countries is at various phases 
of development, but for most of the markets creation of an HTA unit and utilization 
of it is the next step in their pharmaceutical market evolution. CONCLUSIONS: 
Developing pharmaceutical markets have become reliant on pharmacoeconomic data 
to determine the true value of innovative pharmaceutical products. The establishment 
of an HTA body in these Asian countries will continue to develop and will become 
an important aspect of their pharmaceutical market expansion, therefore the subject 
matter warrants further research and attention. 
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ANALYSIS OF THE TECHNICAL EFFICIENCY IN THREE TEACHING 
HOSPITALS IN MALAYSIA
Moshiri H, Aljunid S
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OBJECTIVES: The measurement of efﬁ ciency is usually the ﬁ rst step in auditing 
performance of hospitals. Measuring hospital efﬁ ciency provides useful information 
for hospital managers. It constitutes the rational framework for the distribution of 
human and other resources between and within hospitals. This study focuses on 
measuring and evaluating technical efﬁ ciency in teaching hospitals at department level 
